A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

$ 14.50

4.9 (624) In stock

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists

Preparation scheme for the isolation of primary liver cells. Liver cell

2023-5892

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). - Abstract - Europe PMC

Inflammatory environment induced in 3D liver NASH model (A) Time course

Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis - ScienceDirect

PDF) A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

IJMS, Free Full-Text

Narrative review of in vitro experimental models of hepatic fibrogenesis - Chiabotto - Digestive Medicine Research

IJMS, Free Full-Text

IJMS, Free Full-Text

Human‐based systems: Mechanistic NASH modelling just around the corner?

Firsocostat treatment leads to decreased lipid accumulation in NASH